NCT00280631 - Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

June 30, 2008

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

DRUG

Ezatiostat Hydrochlorine

Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.

Trial Locations (3)

Loyola University Chicago-Cardinal Bernardin Cancer Center, Maywood

Loyola University Medical Center, Maywood

University of Massachusetts (UMass) Memorial Medical Center, Worcester